Thursday, 18th November Clinical Oncology Society of Australia Annual Scientific Meeting 2021

Co-chair: Susan Fraser

Professor John Hopper:

Centre for Epidemiology & Biostatistics / Melbourne School of Population & Global Health, The University of Melbourne

Adjunct Professor Thomas Lloyd

Department of Diagnostic Radiology, Princess Alexandra Hospital; Metro South Health, Brisbane; Visiting Radiologist Breastscreen Queensland; Adjunct Professor - Faculty of Health, QUT

Associate Professor Carolyn Nickson
Melbourne School of Population and Global Health, The University of Melbourne; Cancer Research Division, Cancer Council NSW; School of Public Health, University of Sydney

Ms Gerda Evans:

Breast Cancer Network Australia and Australian Breast Density Consumer Advisory Council (Co-Chair)

Associate Professor Jennifer Stone

School of Population and Global Health, University of Western Australia

Associate Professor Haitham Tuffafa

Centre for the Business and Economics of Health, The University of Queensland

This conference acknowledges the sponsorship of 

Title - Quality of life matters to MBC patients
Time - 7:30am - 8:30am
Chairperson - Prof Elgene Lim
Speakers -

• Prof Elgene Lim, Medical Oncologist, Kinghorn Cancer Centre & St Vincents Clinic, and Laboratory head, Connie Johnson Breast Cancer Research Group, Garvan Institute of Medical Research

• Dr Rachel Dear, Medical Oncologist, The Kinghorn Cancer Centre, St Vincent’s Hospital

• A/Prof Yoland Antill, Medical Oncologist, Cabrini Health

Description - Lilly kindly invites you to participate in our live breakfast symposium where our panel of clinicians: Prof Elgene Lim, Dr Rachel Dear and A/Prof Yoland Antill will present and discuss “Quality of Life matters to MBC patients”. This symposium will discuss the Quality of Life (QoL) considerations for patients with metastatic breast cancer when managing with Verzenio treatment in the clinic and the patient reported outcomes in the pivotal Monarch 2 and 3 studies. The panel will be taking questions from the audience throughout the talk and look forward to an interactive session with the COSA attendees.

Title - Venous thromboembolism management in patients with cancer
Time - 7:30am - 8:30am
Chairperson - Prof Desmond Yip – Clinical Director of Medical Oncology, The Canberra Hospital
Speakers -

• Dr Scott Dunkley – Haematologist, Royal Prince Alfred Hospital, Sydney

• Prof Harshal Nandurkar- Director of Clinical Haematology, Alfred Health; Director, Alfred Cancer Program & Head of the Australian Centre for Blood Diseases

• Prof Simon Noble - Marie Curie Professor in Supportive and Palliative Medicine, Cardiff University, Cardiff, UK

Description - Venous thromboembolism (VTE) is an unfortunately common complication in patients with active cancer. Data suggests that one or more episodes of VTE is experienced by around 15% of patients with cancer throughout the course of their disease. [1] With the recent emergence of data on the use of direct oral anticoagulants (DOACs), clinicians involved in the care of cancer patients need to be aware of emerging treatment options for VTE as this is an area where patients face an increased burden due to daily injections of low molecular weight heparin (LMWH) for the treatment of VTE, in addition to complex cancer treatment. During this symposium the latest clinical data on the use of DOACs in treatment of VTE associated with cancer will be discussed by experts in the field including a palliative care specialist, haematologists, and a medical oncologist. In select patient groups without high bleeding risk, oral treatment with DOACs may be a reasonable alternative for the treatment of VTE, potentially improving patient comfort and compliance to treatment.

[1] Noble S, Pasi J. Epidemiology and pathophysiology of cancer associated thrombosis. Br J Cancer 2010;102(Suppl 1):S2–S9

Morning symposia hosted by BMS-Pfizer Alliance

• Checkpoint Blockade Therapy for Melanoma: Combinations to Improve Outcomes - Jedd Wolchok
• Immunotherapy for Mesothelioma – at the crossroads - Anna Nowak
• Immunotherapy using checkpoint blockade in patients with rare cancers - Oliver Klein

• Implementing psychosocial PROM in routine clinical practice: Challenges and strategies - Phyllis Butow
• The activities and costs of planning for PROMs implementation - Raymond Chan
• The joys AND heartache of implementing PROMs in routine care - Afaf Girgis
• Patient Reported Measures: Driving systems transformation through measuring what matters - Melissa Tinsley

• Immunotherapy and the Microbiome - Miles C Andrews
• Cannabis, alternative medicines and  immunotherapy - Peter Smith
• The role of biomarkers to guide personalized cancer care - Sara Pai
• Good timing! The science of neoadjuvant immunotherapy - Elizabeth Ahern

• Optimal care pathways (OCPs) – driving quality cancer care - Robert Thomas
• Opportunities to improve cancer outcomes for Indigenous Australians - Jacinta Elston
• From OCP to ACP - Cleola Anderiesz

11:45 AM Panel Discussion 

• Finding My Way in the real world: how do outcomes of a digital psycho-oncology program compare from clinical trial to implementation? - Lisa Beatty
• Generating evidence for strategic funding of cancer research: Cancer Australia’s audits of funding in Australia to cancer research projects and research programs 2012 – 2020 - Debra Hector
• Co-designing Healthy Living after Cancer Online, an online nutrition, physical activity, and psychosocial intervention for post-treatment cancer survivors.   - Morgan Leske
• How do we improve nutrition care and information for cancer patients? Exploration of patient, carer and health professional access, perceptions and practices: a mixed-methods study. - Jenelle Loeliger
• Perspectives of health professionals and Aboriginal and Torres Strait Islander people on a potential lung cancer screening program in Australia  - Vivienne Milch, Tom Calma and Tiernan Campbell-O'Brien
• A comprehensive index of implementation strategies to embed smoking cessation interventions into health services: Findings from a systematic review - Anna Ugalde

• COVID-19 prompts rapid and safe transition of chemotherapy into homes - Julie Adams
• Teletrial model (TTM) as a new paradigm of trial conduct: assessing the impact on equity of access, accrual, retention, and safety - Kate Burbury
• The Australian Rare Cancer Portal: A retrospective review of referring oncologist’s service requests. - Reece Caldwell
• Variability across Victorian hospitals in the care of patients with metastatic colorectal cancer: using comprehensive registry data to explore potential quality indicators. - Catherine Dunn
• Variations in Chemotherapy Prescribing Practices in New South Wales - Nasreen Kaadan
• Estimating the need for radiotherapy in older women with breast cancer - Penny Mackenzie

• COVID-19 Vaccine response in cancer patients - Eva Segelov
• Clinical and system implications of COVID-19 on cancer care - Vivienne Milch
• Stakeholder perspectives on the impact of COVID-19 on oncology services: A qualitative study - Joanne Shaw
• A cancer journey through COVID - Deborah Maher

• COSA Presidential Lecture - The Killer Defence - Peter Doherty

Facilitator: Adam Spencer

Panellists:
- Clare Delaney
- Peter Doherty
- Oliver Klein
- Anna McRae-Anderson
- Robyn Ward